Skip to main content

Table 2 Adherence with local guidelines

From: In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis

Diagnosis confirmed clinically and biochemically 100%
Removal of potential culprit drugs 100%
Exclusion of adrenal / thyroid pathology 100%
Documentation of fluid balance status and charts 92%
Documentation of 48 h fluid restriction prior to starting Tolvaptan 96%
Tolvaptan initiation according to Trust policy 96%
Na level monitoring before/after initiation as per recommendations 96%